1 |
Rai N, Kaushik P, Rai A. Development of rabies DNA vaccine using a recombinant plasmid. Acta Virol 2005;49:207-10.
|
2 |
Tebas P, Yang S, Boyer JD, Reuschel EL, Patel A, Christensen-Quick A, et al. Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: a preliminary report of an open-label, Phase 1 clinical trial. EClinicalMedicine 2021;31:100689.
DOI
|
3 |
Magnusson SE, Altenburg AF, Bengtsson KL, Bosman F, de Vries RD, Rimmelzwaan GF, et al. Matrix-MTM adjuvant enhances immunogenicity of both protein- and modified vaccinia virus Ankara-based influenza vaccines in mice. Immunol Res 2018;66:224-33.
DOI
|
4 |
Reimer JM, Karlsson KH, Lovgren-Bengtsson K, Magnusson SE, Fuentes A, Stertman L. Matrix-MTM adjuvant induces local recruitment, activation and maturation of central immune cells in absence of antigen. PLoS One 2012;7:e41451.
DOI
|
5 |
Arunachalam PS, Walls AC, Golden N, Atyeo C, Fischinger S, Li C, et al. Adjuvanting a subunit COVID-19 vaccine to induce protective immunity. Nature 2021;594:253-8.
DOI
|
6 |
Guo W, Duan K, Zhang Y, Yuan Z, Zhang YB, Wang Z, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18 years or older: a randomized, double-blind, placebo-controlled, phase 1/2 trial. EClinicalMedicine 2021;38:101010.
DOI
|
7 |
Beatty AL, Peyser ND, Butcher XE, Cocohoba JM, Lin F, Olgin JE, et al. Analysis of COVID-19 vaccine type and adverse effects following vaccination. JAMA Netw Open 2021;4:e2140364.
DOI
|
8 |
Ott JJ, Wiersma ST. Single-dose administration of inactivated hepatitis A vaccination in the context of hepatitis A vaccine recommendations. Int J Infect Dis 2013;17:e939-44.
DOI
|
9 |
Tanriover MD, Doganay HL, Akova M, Guner HR, Azap A, Akhan S, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet 2021;398:213-22.
DOI
|
10 |
Buller RE, Runnebaum IB, Karlan BY, Horowitz JA, Shahin M, Buekers T, et al. A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer. Cancer Gene Ther 2002;9:553-66.
DOI
|
11 |
Sadoff J, Le Gars M, Shukarev G, Heerwegh D, Truyers C, de Groot AM, et al. Interim results of a phase 1-2a trial of Ad26. COV2.S COVID-19 vaccine. N Engl J Med 2021;384:1824-35.
DOI
|
12 |
Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet 2021;397:671-81.
DOI
|
13 |
Eichinger S, Warkentin TE, Greinacher A. Thrombotic thrombocytopenia after ChAdOx1 nCoV-19 vaccination: reply. N Engl J Med 2021;385:e11.
DOI
|
14 |
Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 2020;367:1260-3.
DOI
|
15 |
Stadler K, Masignani V, Eickmann M, Becker S, Abrignani S, Klenk HD, et al. SARS: beginning to understand a new virus. Nat Rev Microbiol 2003;1:209-18.
DOI
|
16 |
World Health Organization (WHO). Tracking SARS-CoV-2 variants [Internet]. Geneva: WHO; 2021 [cited 2021 Dec 14]. https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/.
|
17 |
World Health Organization (WHO). WHO coronavirus (COVID-19) dashboard [Internet]. Geneva: WHO; 2021 [cited 2021 Dec 14]. https://covid19.who.int/.
|
18 |
World Health Organization (WHO). Weekly epidemiological update on COVID-19-25 [Internet]. Geneva: WHO; 2022 [cited 2022 Jan 17]. https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---25-january-2022.
|
19 |
Centers for Disease Control and Prevention (CDC). COVID data tracker: variant proportions [Internet]. Atlanta: CDC; 2022 [cited 2022 Jan 17]. https://covid.cdc.gov/covid-data-tracker/#monitoring-varaint-heading.
|
20 |
Bansal A, Trieu MC, Mohn KGI, Cox RJ. Safety, immunogenicity, efficacy and effectiveness of inactivated influenza vaccines in healthy pregnant women and children under 5 years: an evidence-based clinical review. Front Immunol 2021;12:744774.
DOI
|
21 |
Centers for Disease Control and Prevention (CDC). Polio vaccination [Internet]. Atlanta: CDC; 2018 [cited 2022 Jan 17]. https://www.cdc.gov/vaccines/vpd/polio/index.html.
|
22 |
Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis 2021;21:181-92.
DOI
|
23 |
Wang H, Zhang Y, Huang B, Deng W, Quan Y, Wang W, et al. Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2. Cell 2020;182:713-21.
DOI
|
24 |
Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis 2021;21:39-51.
DOI
|
25 |
Li XN, Huang Y, Wang W, Jing QL, Zhang CH, Qin PZ, et al. Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative case-control real-world study. Emerg Microbes Infect 2021;10:1751-9.
DOI
|
26 |
Tatsis N, Ertl HC. Adenoviruses as vaccine vectors. Mol Ther 2004;10:616-29.
DOI
|
27 |
Dolzhikova IV, Zubkova OV, Tukhvatulin AI, Dzharullaeva AS, Tukhvatulina NM, Shcheblyakov DV, et al. Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: an open phase I/II trial in healthy adults in Russia. Hum Vaccin Immunother 2017;13:613-20.
DOI
|
28 |
Bar-On YM, Goldberg Y, Mandel M, Bodenheimer O, Freedman L, Alroy-Preis S, et al. Protection against COVID-19 by BNT162b2 booster across age groups. N Engl J Med 2021;385:2421-30.
DOI
|
29 |
Barda N, Dagan N, Ben-Shlomo Y, Kepten E, Waxman J, Ohana R, et al. Safety of the BNT162b2 mRNA COVID-19 vaccine in a nationwide setting. N Engl J Med 2021;385:1078-90.
DOI
|
30 |
Colella G, Orlandi M, Cirillo N. Bell's palsy following COVID-19 vaccination. J Neurol 2021;268:3589-91.
DOI
|
31 |
Astuti I. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): an overview of viral structure and host response. Diabetes Metab Syndr 2020;14:407-12.
DOI
|
32 |
Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med 2020;383:2603-15.
DOI
|
33 |
Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet 2020;396:467-78.
DOI
|
34 |
Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet 2021;397:881-91.
DOI
|
35 |
Anderson EJ, Rouphael NG, Widge AT, Jackson LA, Roberts PC, Makhene M, et al. Safety and immunogenicity of SARSCoV-2 mRNA-1273 vaccine in older adults. N Engl J Med 2020;383:2427-38.
DOI
|
36 |
Health Alert Network; Centers for Disease Control and Prevention (CDC). Emergency preparedness and response: cases of cerebral venous sinus thrombosis with thrombocytopenia after receipt of the Johnson & Johnson COVID-19 vaccine [Internet]. Atlanta: CDC; 2021 [cited 2022 Jan 17]. https://emergency.cdc.gov/han/2021/han00442.asp.
|
37 |
Thomas SJ, Moreira ED Jr, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine through 6 months. N Engl J Med 2021;385:1761-73.
DOI
|
38 |
Tarke A, Sidney J, Methot N, Yu ED, Zhang Y, Dan JM, et al. Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals. Cell Rep Med 2021;2:100355.
DOI
|
39 |
Ahmed SF, Quadeer AA, McKay MR. SARS-CoV-2 T cell responses elicited by COVID-19 vaccines or infection are expected to remain robust against Omicron. Viruses 2022;14:79.
DOI
|
40 |
Sahin U, Muik A, Vogler I, Derhovanessian E, Kranz LM, Vormehr M, et al. BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. Nature 2021;595:572-7.
DOI
|
41 |
Stanojevic M, Geiger A, Ostermeier B, Sohai D, Lazarski C, Lang H, et al. Spike-directed vaccination elicits robust spike-specific T-cell response, including to mutant strains. Cytotherapy 2022;24:10-5.
DOI
|
42 |
Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness of COVID-19 vaccines against the B.1.617.2 (Delta) variant. N Engl J Med 2021;385:585-94.
DOI
|
43 |
Perrie Y, Crofts F, Devitt A, Griffiths HR, Kastner E, Nadella V. Designing liposomal adjuvants for the next generation of vaccines. Adv Drug Deliv Rev 2016;99(Pt A):85-96.
DOI
|
44 |
El Sahly HM, Baden LR, Essink B, Doblecki-Lewis S, Martin JM, Anderson EJ, et al. Efficacy of the mRNA-1273 SARSCoV-2 vaccine at completion of blinded phase. N Engl J Med 2021;385:1774-85.
DOI
|
45 |
Kodihalli S, Kobasa DL, Webster RG. Strategies for inducing protection against avian influenza A virus subtypes with DNA vaccines. Vaccine 2000;18:2592-9.
DOI
|
46 |
Castiello T, Georgiopoulos G, Finocchiaro G, Claudia M, Gianatti A, Delialis D, et al. COVID-19 and myocarditis: a systematic review and overview of current challenges. Heart Fail Rev 2022;27:251-61.
DOI
|
47 |
Repajic M, Lai XL, Xu P, Liu A. Bell's Palsy after second dose of Pfizer COVID-19 vaccination in a patient with history of recurrent Bell's palsy. Brain Behav Immun Health 2021;13:100217.
DOI
|
48 |
Self WH, Tenforde MW, Rhoads JP, Gaglani M, Ginde AA, Douin DJ, et al. Comparative effectiveness of moderna, Pfizer-BioNTech, and Janssen ( Johnson & Johnson) vaccines in preventing COVID-19 hospitalizations among adults without immunocompromising conditions: United States, March-August 2021. MMWR Morb Mortal Wkly Rep 2021;70:1337-43.
DOI
|
49 |
Ozonoff A, Nanishi E, Levy O. Bell's palsy and SARS-CoV-2 vaccines. Lancet Infect Dis 2021;21:450-2.
DOI
|
50 |
Teixeira FM, Teixeira HC, Ferreira AP, Rodrigues MF, Azevedo V, Macedo GC, et al. DNA vaccine using Mycobacterium bovis Ag85B antigen induces partial protection against experimental infection in BALB/c mice. Clin Vaccine Immunol 2006;13:930-5.
DOI
|
51 |
Pallesen J, Wang N, Corbett KS, Wrapp D, Kirchdoerfer RN, Turner HL, et al. Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proc Natl Acad Sci U S A 2017;114:E7348-57.
|
52 |
Pepin S, Dupuy M, Borja-Tabora CF, Montellano M, Bravo L, Santos J, et al. Efficacy, immunogenicity, and safety of a quadrivalent inactivated influenza vaccine in children aged 6-35 months: a multi-season randomised placebo-controlled trial in the Northern and Southern hemispheres. Vaccine 2019;37:1876-84.
DOI
|
53 |
Russell WC. Adenoviruses: update on structure and function. J Gen Virol 2009;90(Pt 1):1-20.
DOI
|
54 |
Bos R, Rutten L, van der Lubbe JE, Bakkers MJ, Hardenberg G, Wegmann F, et al. Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses. NPJ Vaccines 2020;5:91.
DOI
|
55 |
Gross R, Zanoni M, Seidel A, Conzelmann C, Gilg A, Krnavek D, et al. Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants. EBioMedicine 2022;75:103761.
DOI
|
56 |
Janeway Jr CA, Travers P, Walport M, Shlomchik MJ. The distribution and functions of immunoglobulin isotypes. In: Janeway Jr CA, Travers P, Walport M, Shlomchik MJ, editors. Immunobiology: the immune system in health and disease. 5th ed. New York: Garland Science; 2001.
|
57 |
Heath PT, Galiza EP, Baxter DN, Boffito M, Browne D, Burns F, et al. Safety and efficacy of NVX-CoV2373 COVID-19 vaccine. N Engl J Med 2021;385:1172-83.
DOI
|